RxDoctor Payments Data

Marty Allen, MD

Infectious Disease · Lexington, KYNPI 1639217391

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $28,730 of the $39,709 with a category attached, or 72.4%. Astellas Pharma US Inc accounts for 91.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2024 at $11,400 and has fallen 65.7% since, to $3,907 in 2025. Among infectious disease clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,709in general payments, 2019–2025

Across 221 payments — averaging $179.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$36K
  • Gilead$1K
  • Viiv Healthcare Company$565
  • Shionogi Inc$504
  • Romark Laboratories, LC$380
  • La Jolla Pharmaceutical Company$205
  • plus $538 from 8 others

What the payments were for

  • Speaking & faculty fees$28,73072%
  • Travel & lodging$5,46814%
  • Food & beverage$5,40214%
  • Education$1100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,709 in reported general payments places this provider in the 90th percentile of 100 infectious disease providers in Kentucky.

See all infectious disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$162,044
Medicare patients
268
Services billed
37,756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala27$99,541
RukobiaFostemsavir Tromethamine11$85,069
Daptomycin50$31,377
ErtapenemErtapenem Sodium13$8,184
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam20$6,304
CeftriaxoneCeftriaxone Sodium39$4,624
Epinephrine15$2,715
CefuroximeCefuroxime Axetil46$2,580
Doxycycline Monohydrate108$2,385
Sodium Chloride0.9 % Sodium Chloride11$1,673
Cephalexin62$1,084
ValacyclovirValacyclovir Hcl20$886
Fluconazole52$877
Doxycycline Hyclate59$754
Potassium Chloride49$544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$1,316$99,54127 claims
Viiv Healthcare CompanyRukobia$565$85,06911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 100 infectious disease providers in Kentucky.

Other infectious disease in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →